RecruitingPhase 1Phase 2NCT05272709

TT-702 in Patients With Advanced Solid Tumours.

CURATE: A Cancer Research UK Phase I/II, Dose Escalation and Expansion Trial of TT-702, A Selective Adenosine A2BR Antagonist, Given Orally as a Monotherapy Agent and in Combination, in Patients With Advanced Solid Tumours

Sponsor

Cancer Research UK

Enrollment

60 participants

Start Date

Jan 19, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study tests TT-702, a new experimental drug, in people with advanced solid tumors — either alone or in combination with darolutamide (a prostate cancer drug). It is a Phase 1 safety and dose-finding trial. **You may be eligible if...** - You have an advanced or metastatic solid tumor for which standard treatments have been exhausted - Your performance status is good (ECOG 0–1) - Your life expectancy is at least 12 weeks - You are willing to provide blood and tissue samples, including a fresh tumor biopsy - For the monotherapy arm: you are 16 or older; for the combination arm with darolutamide: 18 or older **You may NOT be eligible if...** - Your performance status is poor - You have serious uncontrolled medical conditions - You are unable or unwilling to undergo tumor biopsy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.